Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
Status:
Active, not recruiting
Trial end date:
2022-05-16
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well pazopanib hydrochloride works in treating patients with
kidney cancer that has spread to other places in the body (metastatic). Pazopanib
hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth. Pazopanib hydrochloride may also stop the growth of kidney cancer by blocking
blood flow to the tumor.